Daptomycin is a cyclic lipopeptide antibiotic derived from the organism Streptomyces roseosporus. Daptomycin is used for the treatment of various bacterial infections caused by Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococci (VRE). Daptomycin has numerous FDA-approved and off-label clinical uses.
FDA-approved clinical uses of daptomycin:
Off-label clinical uses of daptomycin include:
Limitations of Use:
Daptomycin is a cyclic lipopeptide antibiotic that exerts its bactericidal effect by disrupting multiple aspects of bacterial cell membrane function. Daptomycin binds to the cell membrane of susceptible organisms and causes a rapid depolarization of membrane potential. The loss of membrane potential leads to the intracellular inhibition of DNA, RNA, and protein synthesis. This ultimately results in bacterial cell death. Daptomycin is only active against gram-positive bacteria.
Daptomycin is FDA-approved for administration by the intravenous route. It is administered every 24 hours in patients with a creatinine clearance greater than 30 mL/min. The frequency of administration in patients with renal impairment (CrCl less than 30 mL/min) is every 48 hours. The dose of daptomycin required is indication specific. The desired dose should be administered over 30 minutes in adults and children over the age of 7. Daptomycin should be infused over 60 minutes in children one to six years of age. Daptomycin can also be administered as an intravenous push over 2 minutes in adult patients only.
Route of Administration: Intravenous
Inhibition of bacterial growth: Bactericidal
PK/PD parameter: AUC:MIC
Absorption: Not applicable
The onset of action: Daptomycin has a rapid onset of action
Distribution: Large volume of distribution at steady-state (approximately 1.0 L/kg) in healthy adult patients. The volume of distribution at steady-state in pediatric and critically-ill patients has been found to be significantly lower.
Protein Binding: 90% to 93%; 84% to 88% in patients with a creatine clearance less than 30 mL/min.
Metabolism: Minimal amounts of oxidative metabolites have been detected. In vitro studies suggest human liver microsomes do not metabolize daptomycin.
Clearance: 8.3 to 9 mL/min/kg in adults with normal renal function. Increased clearance has been demonstrated in pediatric patients.
Half-life: 8 to 9 hours in healthy adults with normal renal function. The elimination half-life can be significantly prolonged in patients with renal impairment (up to 28 hours). Shorter elimination half-life has been noted in pediatric patients.
Excretion: Daptomycin is primarily eliminated as unchanged drug in the urine (78%) with a lesser amount eliminated in feces (5.7%).
Adverse effects associated with daptomycin therapy include myopathy/rhabdomyolysis, eosinophilic pneumonia, and anaphylactic hypersensitivity reactions. Patients may also experience less severe adverse effects such as constipation, headache, insomnia, and skin rash.
Daptomycin is associated with an increased incidence of myopathy and rhabdomyolysis. Cases have been reported in patients with and without acute renal failure. Therefore weekly monitoring of creatine phosphokinase (CPK) levels is recommended in patients receiving daptomycin therapy. More frequent monitoring is recommended in patients with renal impairment and/or those receiving concomitant HMG CoA reductase inhibitors (statins). Treatment should be discontinued in patients with signs and symptoms of myopathy in conjunction with an elevated CPK (greater than five times ULN or greater than 1000 units/L) and in asymptomatic patients with a CPK elevation greater than ten times ULN (greater than 2000 units/L). The incidence of myopathy has been shown to increase with administration of greater than the recommended dosage. Additionally, providers should consider temporarily discontinuing other agents associated with rhabdomyolysis (e.g., HMG-CoA reductase inhibitors) during daptomycin therapy.
Daptomycin therapy is also associated with the development of eosinophilic pneumonia, which generally occurs 2 to 4 weeks after initiating therapy. Patients should be monitored for signs and symptoms of eosinophilic pneumonia, including new onset or worsening fever, and new infiltrate on chest imaging. Daptomycin therapy should be immediately discontinued for patients who experience signs and symptoms of eosinophilic pneumonia, and appropriate treatment should be initiated. It is important to note that the incidence of eosinophilic pneumonia may reoccur with re-exposure to daptomycin.
Rare cases of peripheral neuropathy have been observed in patients receiving daptomycin. Monitoring for new onset or worsening neuropathy is recommended.
It is important to note that prolonged use of daptomycin can lead to the development of a superinfection such as Clostridium difficile-associated diarrhea (CDAD) and pseudomembranous colitis. The incidence of CDAD has been observed greater than two months after treatment with daptomycin.
Daptomycin is contraindicated in patients with a known hypersensitivity reaction to the drug or any component within the formulation.
Although daptomycin does not have other contraindications to its use, there are important clinical considerations to keep in mind when caring for patients.
Elderly patients are at an increased risk of daptomycin toxicity due to age-related changes in renal function or factors that may enhance the exposure to the medication. However, no dosage adjustments are recommended for patients with a creatinine clearance greater than 30 mL/min.
Daptomycin is pregnancy category B; however, there is still limited information available on the use of daptomycin during pregnancy. Case reports describe the successful use of daptomycin during second and third trimesters of pregnancy. Additionally, animal reproductive studies have not yet determined any evidence of fetal harm from maternal use of daptomycin. Nevertheless, a risk-benefit analysis should be conducted before initiating daptomycin in pregnant patients.
Low concentrations of daptomycin have been detected in breast milk (0.1% of the maternal dose). Currently, there is no information available on the effects of daptomycin on breastfed infants or milk production. Like other antibiotics, maternal use of daptomycin may cause a non-dose related change in bowel flora. Therefore, breastfed infants should be monitored for gastrointestinal disturbances. Breastfeeding mothers who are receiving treatment with daptomycin should be advised to consult with their provider and conduct a risk-benefit analysis prior to breastfeeding.
Reduced renal function can lead to accumulation of daptomycin, thereby increasing the risk of adverse effects. Dose adjustments are necessary for patients with a creatinine clearance less than 30 mL/min, including patients receiving hemodialysis or continuous ambulatory peritoneal dialysis (CAPD). It is recommended that renal function and creatinine phosphokinase (CPK) levels be monitored multiple times a week in patients with renal impairment.
Like with other antibiotics, prolonged or inappropriate treatment with daptomycin can lead to bacterial resistance. It is important for providers to be aware of increased antibiotic resistance patterns and practice appropriate antimicrobial stewardship. Patients should be counseled on the importance of medication adherence to prevent the development of multidrug-resistant infections.
Other medications taken along with daptomycin may increase the risk of adverse effects and drug toxicity. Therefore dosing adjustments, additional monitoring, and consideration of alternative treatment should be considered when combining daptomycin with certain medications. Caution is advised when administering daptomycin with HMG-CoA reductase inhibitors, (statins) as this can potentially increase the risk of skeletal muscle toxicity. It is recommended that administration of HMG-CoA reductase inhibitors be temporarily discontinued while patients receive treatment with daptomycin. If the concomitant administration cannot be avoided, close monitoring of creatinine phosphokinase should be instated at least once-weekly.
Patients receiving daptomycin therapy should be monitored to ensure safe administration of the medication. Baseline renal function tests are recommended to assess the presence of renal impairment and necessity of dosage adjustments. Additionally, it is recommended that clinicians obtain baseline creatinine phosphokinase (CPK) levels in patients requiring treatment for greater than 1 week. After that, the CPK should be monitored at least once-weekly. More frequent monitoring of CPK is necessary for patients with current or prior statin therapy, an unexplained elevation in CPK, or renal impairment.
Patients should also be monitored for muscle pain or weakness, new onset or worsening peripheral neuropathy, and signs or symptoms of eosinophilic pneumonia. Furthermore, patients who develop diarrhea should be tested for C. difficile infection.
Potentially serious adverse drug events associated with daptomycin therapy include eosinophilic pneumonia and myopathy/rhabdomyolysis.